Skip to content

Phase I trial for safety and feasibility of steady pressure automatically controlled endoscopy (SPACE).

Phase I trial for safety and feasibility of steady pressure automatically controlled endoscopy (SPACE). - Phase I trial for SPACE.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005434
Enrollment
10
Registered
2011-04-14
Start date
2011-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial esophageal cancer

Interventions

Esophageal ESD with steady pressure automatically controlled endoscopy

Sponsors

Japan SPACE study group
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) To be diagnosed as SCC or High grade intraepithelial neoplasia by endoscopic forceps biopsy. 2) The invasion depth is diagnosed endoscopically as T1a-EP or T1a-LPM. 3) The lesion occupies less than 2/3 of the circumference of esophagus. 4) Without past history of esophagectomy. 5) Not to be involved cervical esophagus or esophago-gastro junction. 6) The age is more than 20 and less than 80. 7) PS (ECOG) is 0 or 1. 8) Not to show significant abnormality by respiratory function test. 9) Main organ function is maintained by blood sampling. 10) Written informed consent has been obtained.

Exclusion criteria

Exclusion criteria: 1) To be affected infectious disease which need systemic treatment. 2) With body temperature higher than 38C 3) To have bleeding tendency. 4) Pregnancy or possibility of pregnancy or breast-feeding woman 5) Psychiatric disease 6) To be treated systemic steroid therapy 7) Unstable angina 8) Uncontrolled hypertension 9) Uncontrolled DM 10) Unable to interrupt anticoaglant for ESD 11) To be judged inapropriate to participate this trial by contact person

Design outcomes

Primary

MeasureTime frame
Rate of adverse event (based on NCI-CTCAE ver. 4.0)

Secondary

MeasureTime frame
1) Completion rate of ESD 2) The changes of pCO2 before and after ESD 3) The changes of vital signs during ESD 4) En bloc margin negative rate of ESD 5) Procedure duration 6) Patients' subjective symptom 7) Dosage amount of sedative during ESD

Countries

Japan

Contacts

Public ContactKiyokazu Nakajima

Osaka University Graduate School of Medicine Department of Gastroenterological Surgery

knakajima@surg1.med.osaka-u.ac.jp06-6876-0550

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026